XRCC2 and central nervous system cancer: Our survival analysis showed that lower grade glioma patients with tumors expressing lower levels of XRCC2 prior to treatment have better outcomes on temozolomide (Fig. 3A), potentially because the function of XRCC2 counteracts the drug’s mechanism of action.